Evidence mapPaperPMID 35543492Full record

ArticleJournal of inherited metabolic disease2022

Research priorities for mitochondrial disorders: Current landscape and patient and professional views.

Rhys H Thomas, Amy Hunter, Lyndsey Butterworth, Catherine Feeney, Tracey D Graves, Sarah Holmes, Pushpa Hossain, Jo Lowndes, Jenny Sharpe, Sheela Upadhyaya and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of inherited metabolic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 3 countries.

Rhys H ThomasTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.ORCID 0000-0003-2062-8623
Amy HunterGenetic Alliance UK, London, UK.ORCID 0000-0001-5076-8761
Lyndsey ButterworthLily Foundation, Warlingham, UK.
Catherine FeeneyNHS Highly Specialised Service for Rare Mitochondrial Diseases, Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.
Tracey D GravesHinchingbrooke Hospital, Huntingdon, UK.
Sarah HolmesThe National Hospital for Neurology and Neurosurgery, London, UK.
Pushpa HossainHCD Economics Ltd, Warrington, UK.
Jo LowndesOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Jenny SharpeCentre for Innovation in Regulatory Science, London, UK.
Sheela UpadhyayaJames Lind Aliance, Southampton, UK.
Kristin N VarhaugTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Marcela VotrubaUniversity Hospital Wales and School of Vision Sciences, Cardiff University, Cardiff, UK.
Russell WheelerLeber's Hereditary Optic Neuropathy Society, Hockley, UK.
Kristina StaleyTwoCan Associates, Herefordshire, UK.
Shamima RahmanMitochondrial Research Group, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.ORCID 0000-0003-2088-730X
Newcastle University · GBCentre for Innovation in Regulatory Science · GBEast Malling Research (United Kingdom) · GBGenetic Alliance UK (United Kingdom) · GBGreat Ormond Street Hospital for Children NHS Foundation Trust · GBHereditary Disease Foundation · USHinchingbrooke Hospital · GBHSBC Holdings · GBJames Lind Institute · CHNational Hospital for Neurology and Neurosurgery · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBOxford University Hospitals NHS Trust · GBTwoCan Associates (United Kingdom) · GBUniversity Hospital of Wales · GB

Funding

Wellcome TrustWellcome Trust 208561/Z/17/Z
6 · The paper itself

Abstract

Primary mitochondrial disorders encompass a wide range of clinical presentations and a spectrum of severity. They currently lack effective disease-modifying therapies and have a high mortality and morbidity rate. It is therefore essential to know that competitively funded research designed by academics meets the core needs of people with mitochondrial disorders and their clinicians. Priority setting partnerships are an established collaborative methodology that brings patients, carers and families, charity representatives and clinicians together to try to establish the most pressing and unanswered research priorities for a particular disease. We developed a web-based questionnaire, requesting all patients affected by primary mitochondrial disease, their carers and clinicians to pose their research questions. This yielded 709 questions from 147 participants. These were grouped into overarching themes including basic biology, causation, health services, clinical management, social impacts, prognosis, prevention, symptoms, treatment and psychological impact. Following the removal of "answered questions", the process resulted in a list of 42 discrete, answerable questions. This was further refined by web-based ranking by the community to 24 questions. These were debated at a face-to-face workshop attended by a diverse range of patients, carers, charity representatives and clinicians to create a definitive "Top 10 of unanswered research questions for primary mitochondrial disorders". These Top 10 questions related to understanding biological processes, including triggers of disease onset, mechanisms underlying progression and reasons for differential symptoms between individuals with identical genetic mutations; new treatments; biomarker discovery; psychological support and optimal management of stroke-like episodes and fatigue.

Indexed as

Biomedical ResearchMitochondrial DiseasesCaregiversHealth PrioritiesHumansSurveys and Questionnairesgene therapypatient involvementprimary mitochondrial diseasepriority setting partnershiptreatment

Identifiers

PMID35543492
PMCPMC9429991
OpenAlexW4280570317

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.